S100A7 is highly expressed in ER?- invasive carcinoma, as well as in high grade ductal carcinomas in situ (DCIS), and therefore may play an important role in breast cancer progression and metastasis. Our preliminary studies indicate that S100A7 has differential effects on ER?+ and ER?- cells;it enhances growth and metastasis in ER?- and inhibits growth in ER?+ breast cancer cells. However, it remains to be determined if and how S100A7 modulates differential effects in ER?+ and ER?- breast cancer subtypes. Our central hypothesis is that the differential effects of S100A7 are a result of two different pathways: in ER?-, it may modulate the tumor microenvironment by binding to receptor for advance glycation end products (RAGE) and transactivating EGFR;in ER?+ cells, it may regulate the 2-catenin pathway. The mortality of patients is significantly caused by the invasive characteristics of ER?-, especially in triple-negative breast cancers, and the development of drug resistance in ER?+ breast cancers;as a result, understanding how S100A7 may modulate differential effects in ER?- and ER?+ breast cancers is of fundamental importance. To this end, we will use an innovative, multi-disciplinary approach to analyze the role and molecular mechanisms of S100A7, taking advantage of transgenic and knockout mouse model systems.
In Aim 1, we will further analyze S100A7 expression in breast cancer tissue microarrays in different grades and subtypes, especially triple-negative breast cancers.
In Aim 2, we will further characterize the role of S100A7 in modulating the growth and metastasis of ER?+ and ER?- cells in in vivo mouse models.
In Aim 3, we will analyze the role of S100A7 in breast cancer progression and metastasis in transgenic and knockout mouse model systems. Finally, in Aim 4, we will delineate the S100A7-mediated molecular mechanisms that enhance growth and metastasis of ER?- cells and inhibit cell proliferation and migration of ER?+ cells. Insight gained from these studies may help in developing novel and innovative therapies for highly invasive ER?- and drug resistant ER?+ breast cancers.

Public Health Relevance

S100A7 is highly expressed in both the aggressive ER?- and high grade ductal carcinoma in situ (DCIS) breast cancer subtypes. However, not much is known about its role in the development and progression of breast cancer. The proposed studies will determine the molecular mechanism by which S100A7 enhances growth and metastasis in ER?- and inhibits growth in ER?+ cells. Understanding the differential role of S100A7 in ER?- and ER?+ breast cancers may provide novel insights for prevention and treatment of highly aggressive and difficult to treat ER?- breast cancers, as well as ER?+ drug resistant breast cancers. In addition, these studies will also provide information about S100A7 expression in different grades and types of breast cancers, especially ER?- basal-type breast cancers.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Project (R01)
Project #
Application #
Study Section
Tumor Progression and Metastasis Study Section (TPM)
Program Officer
Sathyamoorthy, Neeraja
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Ohio State University
Schools of Medicine
United States
Zip Code
Oghumu, Steve; Varikuti, Sanjay; Terrazas, Cesar et al. (2014) CXCR3 deficiency enhances tumor progression by promoting macrophage M2 polarization in a murine breast cancer model. Immunology 143:109-19
Wani, Nissar; Nasser, Mohd W; Ahirwar, Dinesh K et al. (2014) C-X-C motif chemokine 12/C-X-C chemokine receptor type 7 signaling regulates breast cancer growth and metastasis by modulating the tumor microenvironment. Breast Cancer Res 16:R54
Ravi, Janani; Sneh, Amita; Shilo, Konstantin et al. (2014) FAAH inhibition enhances anandamide mediated anti-tumorigenic effects in non-small cell lung cancer by downregulating the EGF/EGFR pathway. Oncotarget 5:2475-86
Chakravarti, Bandana; Ravi, Janani; Ganju, Ramesh K (2014) Cannabinoids as therapeutic agents in cancer: current status and future implications. Oncotarget 5:5852-72
Zhao, Helong; Anand, Appakkudal R; Ganju, Ramesh K (2014) Slit2-Robo4 pathway modulates lipopolysaccharide-induced endothelial inflammation and its expression is dysregulated during endotoxemia. J Immunol 192:385-93
Sneh, Amita; Deol, Yadwinder S; Ganju, Akaansha et al. (2013) Differential role of psoriasin (S100A7) in estrogen receptor * positive and negative breast cancer cells occur through actin remodeling. Breast Cancer Res Treat 138:727-39
Nasser, Mohd W; Qamri, Zahida; Deol, Yadwinder S et al. (2012) S100A7 enhances mammary tumorigenesis through upregulation of inflammatory pathways. Cancer Res 72:604-15
Deol, Yadwinder S; Nasser, Mohd W; Yu, Lianbo et al. (2011) Tumor-suppressive effects of psoriasin (S100A7) are mediated through the ýý-catenin/T cell factor 4 protein pathway in estrogen receptor-positive breast cancer cells. J Biol Chem 286:44845-54